Osteoporosis Clinical Trial
Official title:
Early Effect of Vitamin D in Primary Hyperparathyroidism
Primary hyperparathyroidism (PHPT) is a common disease that occurs in 1 in 10,000 people
every year. In the presence of this condition, the parathyroid glands produce excessive
amounts of parathyroid hormone (PTH), which regulates calcium levels. The high levels of
parathyroid hormone remove too much calcium from bones, and then deposit the excess calcium
in the blood, which is then filtered into the urine by the kidneys. Bone health is
threatened by excess calcium loss which weakens bone structure. Other affected organs
include the skeleton (calcium loss leads to a "weakening" of the skeleton), and the kidneys
(high blood calcium can lead to kidney stones).
It is now evident that the majority of patients with even mild Primary Hyperparathyroidism
are vitamin D deficient. In 2009, new international guidelines for the management of
asymptomatic PHPT direct physicians to measure 25-hydroxyvitamin D (D3 or 25-OHD) in all
patients, and to replete the reserve of vitamin D when the level is low (< 20 ng/ml).
However, no recommendations for vitamin D repletion are given, because of limited data
regarding the effects of vitamin D repletion, appropriate dosing and safety. Therefore,
there is an urgent need for data upon which to base such recommendations, as well as are
data on the effects of such treatment upon bones.
Subjects with low vitamin D3 levels will be selected for this trial. They will be given
enough vitamin D3 to raise their low blood levels from a low to a normal range. The
assessments in this study, including the quadruple label bone biopsy, will allow us to
document the short term effects of administering vitamin D3 on changes in bone.
All participants enrolled in this trial will be vitamin D3 deficient. Participants will take
an antibiotic (tetracycline) 4 times a day to mark the starting point from which bone
changes will be assessed. After 3 days of tetracycline, a 12 week course of vitamin D3 or
placebo will be initiated. Six of 7 participants will receive the study drug (active vitamin
D3), while 1 in 7 will receive a placebo (sugar pill). Ten weeks later, another 3-day course
of tetracycline will be given. At the end of 12 weeks, a bone biopsy will be done. A small
piece of bone (about the size of a pencil eraser) will be removed from the hip (iliac
crest). The bone will be analyzed to determine the effect of vitamin D3 on primary
hyperparathyroidism.
There will be 4 study visits: Screening, Baseline, Week 8, and Week 12 when the bone biopsy
will be performed.
Study Procedures:
Medical and Social History
Blood tests (drawn at the study center and local Quest Lab)
24-Hour urine collection for calcium and creatinine excretion
Abdominal X-ray (to assess for kidney stones)
Transiliac crest Bone Biopsy
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06287502 -
Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis
|
N/A | |
Completed |
NCT03822078 -
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women
|
Phase 1 | |
Recruiting |
NCT05845021 -
Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty
|
N/A | |
Completed |
NCT00092066 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
|
Phase 3 | |
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04736693 -
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
|
||
Not yet recruiting |
NCT06431867 -
Primary Care Management of Osteoporosis in Older Women
|
||
Completed |
NCT02922478 -
Role of Comorbidities in Chronic Heart Failure Study
|
||
Recruiting |
NCT02616627 -
Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
|
||
Recruiting |
NCT02635022 -
Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
|
||
Active, not recruiting |
NCT02617303 -
Prevention of Falls and Its Consequences in Elderly People
|
N/A | |
Completed |
NCT02566655 -
Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis
|
Phase 1 | |
Completed |
NCT03420716 -
Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women
|
N/A | |
Completed |
NCT02559648 -
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
|
Phase 2 | |
Not yet recruiting |
NCT02223572 -
Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture
|
N/A | |
Completed |
NCT02003716 -
DeFRA Questionnaire as an Anamnestic Form
|
N/A | |
Not yet recruiting |
NCT01854086 -
Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday
|
N/A | |
Unknown status |
NCT01913834 -
Nasally and sc Administered Teriparatide in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02143674 -
Muscle Strengthening Exercises and Global Stretching in Elderly
|
N/A | |
Completed |
NCT01757340 -
Calorie Restriction With Leucine Supplementation
|
N/A |